Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

Authors
Qaseem, Amir
Yost, Jennifer
Etxeandia-Ikobaltzeta, Itziar
Abraham, George M.
Jokela, Janet A.
Forciea, Mary Ann
Miller, Matthew C.
Humphrey, Linda L.
UMass Chan Affiliations
Department of Medicine
Document Type
Journal Article
Publication Date
2021-02-09
Keywords
remdesivir
hospitalized patients
coronavirus disease 2019
COVID-19
effectiveness
harms
Health Services Administration
Health Services Research
Infectious Disease
Internal Medicine

Metadata
Show full item record
Link to Full Text
https://doi.org/10.7326/m20-8101
Abstract
Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?
Source

Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-8101. Epub ahead of print. PMID: 33560862. Link to article on publisher's site
DOI
10.7326/M20-8101
Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27381
PubMed ID
33560862
Related Resources

Link to Article in PubMed
Collections